ImmunityBio presented "Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer receiving IL-15R⍺Fc superagonist N-803 plus BCG" at the ASCO GU conference in San Francisco.
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
ImmunityBio presented favorable QOL data from its Phase 2/3 trial in bladder cancer
CLINICAL AND REGULATORY
ImmunityBio presented QOL in Quilt 3.032 study in bladder cancer patients
The FDA is currently reviewing the BLA for ImmunityBio’s N-803 plus BCG for the treatment of NMIBC CIS with a PDUFA date of May 23, 2023. A positive difference in physical function in responders versus non-responders was noted. The study indicates a favorable risk/benefit ratio and quality of life following N-803 plus BCG is comparable to BCG alone.
